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Case Report

A 67 year-old male with a past medical history of hypertension
and insulin-dependent type II diabetes complicated by
neuropathy, retinopathy, and chronic kidney disease presented
to the hospital with a complaint of fatigue. The patient noted
generalized weakness that had begun the morning of admission
after two days of malaise and subjective fever. This weakness
prevented him from being able to rise from a sitting position,
resulting in a fall off the couch. He denied injury from this fall
along with shortness of breath or chest pain, however, he did
admit to two episodes of vomiting the day prior to admission.
The patient was taking the following medications: furosemide,
aspirin, isosorbide mononitrate, lipitor, levothyroxine,
candesartan, metoprolol, clopidogrel, doxazosin, calcitriol
and Insulin 70/30. Medical history included, hyperlipidemia,
hypothyroidism, benign prostatic hypertrophy, stable angina,
and peripheral vascular disease along with the conditions
listed above. Past surgical history included 2 stents in the LAD
coronary artery, vitrectomy, and transurethral resection of the
prostate (TURP). Additionally, the patient noted that he lived
alone after having retired from teaching and denied any drugs,
smoking or alcohol.
On physical exam, the patient was febrile at 102.2°F, heart rate
was 99, respiratory rate was 17, and blood pressure was elevated
at 183/56 mmHg. Generally, the patient was dehydrated
and appeared to be somnolent but responsive to questions.
Neurological exam was remarkable for generalized bilateral
upper and lower extremity weakness and asterixis with no
focal neurological deficits. His cranial nerves were intact. Skin
exam was significant for a warm, erythematous, blanching,
non-pruritic rash on the left anterior tibial surface, as well as an
eschar on the 2nd toe of the left foot. The rest of physical exam
was within normal limits.
An arterial blood gas was performed due to his overall lethargic
state and demonstrated a pH of 7.34, PCO2 34, PO2 66 and
oxygen saturation of 91% on room air. His electrolytes were Na
134, K 5.3, Cl 106, HCO3 19, significant for a non-anion gap
metabolic acidosis with a compensatory respiratory alkalosis.
Glucose was elevated at 412mg/dl. Additional laboratory values
revealed a BUN of 79 and creatinine of 3.1 (previous baseline
of 2.3). Urine studies showed protein >300 mg/dl, urine pH of
5.5, urine glucose 500, and rare hyaline casts. Urine electrolytes
results included Na 49, K 30.2, Cl 54, and Cr of 98.7. Lactate was
within normal limits.
The patient was treated acutely for dehydration and
hyperglycemia with intravenous fluids and insulin. He was
started on broad spectrum antibiotics for suspected cellulitis
and osteomyelitis of the 2nd left toe. The combined results of
the urine anion gap of + 25.2, the serum anion gap of 9, and

hyperkalemia led us to a preliminary diagnosis of renal tubular
acidosis type IV. Finally, the renin level returned low at 1.4 ng/
mL/hr (normal 1.9-3.7) indicating a low renin – low aldosterone
as an underlying cause of the metabolic acidosis.

Discussion

Type 4 Renal Tubular Acidosis is characterized by a low
renin - low aldosterone state and non anion-gap metabolic
acidosis. Low aldosterone levels impair the normal functioning
of the Na-K-2Cl cotransporter in the distal nephron. This
deficiency results in decreased reabsorption of Na+ in the
distal nephron and decreased excretion of K+ and H+. Thus,
RTA IV is characterized by salt wasting, hyperkalemia and
acidosis.
RTA IV is caused by a decrease in ammonia recycling in medullary
segments of the nephron and the subsequent increased gradient
for alpha-intercalated cells of the collecting duct to pump
protons against. In order to understand how ammonia recycling
is affected in this condition we will examine the nephron from
proximal to distal and discuss how hyperkalemia and acidosis
derange normal physiology.
There are two mechanisms which are believed to be involved
with the dysfunction of ammonia recycling. In the proximal
convoluted tubule the presence of hyperkalemia creates an
extracellular acidosis and intracellular alkalosis. In the loop of
henle, there is competition between NH4+ and K+ for transport
in the thick ascending loop by the Na+/K+/2Cl- transporter.
In the proximal convoluted tubule, hyperkalemia leads to diffusion
of K+ across all cell membranes. In order to maintain electrical
neutrality, H+ diffuses out of the cell into the extracellular
space. This leads to an extracellular acidosis and an intracellular
alkalosis. The intracellular alkalosis inhibits the de-amination
of glutamine and the subsequent exchange of NH4+ with Na+
in the renal proximal collective tubule (PCT). The deficit of
ammonium produced in the PCT makes less ammonia available
in the ammonia recycling system of the renal medulla.1
In the loop of henle, hyperkalemia is believed to contribute to
the acidosis by limiting the amount of ammonia/ammonium
reabsorbed. Renal medullary ammonia recycling is reduced
through hyperkalemia affecting the Na-K-2Cl cotransporter
in the thick ascending limb. This cotransporter can take one
ion of K+ or NH4+ across the luminal membrane of the thick
ascending limb along with a Na ion and two Cl- ions. NH4+
and K+ directly compete for reabsorption. Under physiological
conditions, NH4+ ions are transported intracellularly, lose their
H+, and NH3 diffuses freely into the medullary interstitium
of the kidney while return to the tubule is prevented by a
membrane that is impermeable to NH3. In the absence of
pathology, the high ammonia concentration in the renal medulla
allows diffusion of NH3 down its concentration gradient into
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the medullary collecting duct or the proximal tubule. Once in
the medullary collecting duct, NH3 can accept a donated H+
ion, becomes ammonium, thereby facilitating the excretion of
an acid load.
Under conditions of RTA IV, there is a lesser amount of
ammonium available for renal medullary recycling, as less
is generated in the proximal convoluted tubule, and this
mechanism for excreting acid is further hampered by the
high potassium in the tubule competing for and displacing
ammonium from the loop cotransporter.2
Therefore, both mechanisms of RTA type 4 work together to
inhibit the excretion of NH3 into the collecting duct of the
kidney and subsequently inhibit the excretion of NH4+ and an
acid load.
Under normal conditions, both mechanisms of hampering renal
medullary ammonia recycling can be repaired by aldosterone,
which promotes the re-absorption of Na and the wasting of K.
However, the hallmark of RTA IV is a low renin/low aldosterone
state. In this situation, it is not possible for normal physiological
mechanisms to break the hyperkalemic acidosis of RTA IV.

Treatment of RTA IV

Treatment of RTA type IV focuses on correction of hyperkalemia,
optimizing renal function, and addressing the physiological
root of the disorder.
Correction of hyperkalemia begins with withholding medications
that can cause or exacerbate hyperkalemia. Potassium-sparing
diuretics, ACE-Inhibitors and ARB medications are common
causes. This is especially important because renal insufficiency in
combination with ACEI/ARB medications can have synergistic
hyperkalemic effects.3

Additionally, if the patient suffers from renal insufficiency
he must be treated to optimize renal function. This includes
omission of medications that aggravate interstitial nephritis
such as NSAIDS, cyclosporine, or tacrolimus.4 Also, adjusting
for pre-renal insufficiency by treating volume status and
maximizing renal perfusion is critical in the process of increasing
potassium excretion. Improving renal function will increase
potassium excretion. For long term management of RTA IV, in
cases of renal insufficiency, dietary sources of potassium must
be limited.
Adrenal insufficiency is suspected in a low renin-low aldosterone
state. It is more common in cases of autoimmune disease and HIV
infection.4 If clinical suspicion is high for adrenal insufficiency,
mineralcorticoids should be given. Fludrocortisone is an effective
exogenous mineralocorticoid replacement.5 However, mineralocorticoid replacement is contraindicated in hypertensive or
edematous patients. Instead, in these patients, hyperkalemia can
be managed with a loop or a thiazide diuretic.
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